Effect of dolomite oral exposure in Wistar rats during organogenesis period of pregnancy.
The potential of oral exposure to dolomite, a natural product that contains calcium and magnesium, to initiate teratogenesis was analyzed in Wistar rats. Animals received dolomite oral dosages of 500 and 1500mg/kg during the period of gestation from day 6-15 post conceptionem (p.c.). Maternal, embryo and fetal toxicity were evaluated. Dolomite exposure did not produce maternal toxicity assessed by clinical observations, body weight gain, hematology parameters and relative organs weight. Signs of embryo-fetal toxicity were not observed. Skeletal malformations and visceral variations were similar in control and dolomite-treated groups. On the other hand, slight increase was observed in fetal body weight in the dolomite-treated group. Treatment with dolomite resulted in significantly decreased incidences of unossified xiphisternum, incomplete ossification of xiphisternum and sternebrae. These effects could be caused by a beneficial influence of calcium and magnesium salts present in dolomite on ossification process. In conclusion, in this study we found that the oral exposure to rats of up to 1500mg/kg of dolomite during organogenesis did not induce significant maternal and embryo-fetal toxicity.
Lagarto
Alicia
A
Drug Research and Development Center, CIDEM, 17 No. 6208 e/ 62 y 64, Playa, Código Postal 11300, Ciudad Habana, Cuba. alicialp@infomed.sld.cu
Bellma
Addis
A
Tillán
Juana
J
Gabilondo
Tatiana
T
Guerra
Isbel
I
Ocanto
Zuleira
Z
Couret
Micaela
M
González
Ricardo
R
D000284:Administration, Oral; D000818:Animals; D001842:Bone and Bones / Q000187:drug effects / Q000196:embryology; D002119:Calcium Carbonate / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D047108:Embryonic Development / Q000187:drug effects*; D005260:Female; D047109:Fetal Development / Q000187:drug effects*; D020567:Fetal Weight / Q000187:drug effects; D008274:Magnesium / Q000633:toxicity*; D018811:Maternal Exposure / Q000009:adverse effects*; D008903:Minerals / Q000633:toxicity*; D019055:No-Observed-Adverse-Effect Level; D038081:Organogenesis / Q000187:drug effects*; D010012:Osteogenesis / Q000187:drug effects; D011247:Pregnancy; D051381:Rats; D017208:Rats, Wistar
D008903:Minerals; D002119:Calcium Carbonate; D008274:Magnesium; C028042:calcium magnesium carbonate